Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on BCT197 Exposure
NCT03498170Phase 1Completed
- Sponsor
- Mereo BioPharma
- Start
- Mar 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acumapimod in chronic obstructive pulmonary disease (COPD), sponsored by Mereo BioPharma. Primary endpoints: Maximum Measurable Plasma Concentration and Area under the plasma concentration-time curve. Started Mar 2018; status: completed.
02
Drugs
acumapimod
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03498170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03498170.